| P2093 | author name string | Lucy Muchiri | |
| | Frank Karlsen | |
| | Margaret Muturi | |
| | Lars E Roseng | |
| | Byamungu Chihongola | |
| | Cosmas Muyabwa | |
| | Serge Bigabwa | |
| P2860 | cites work | Can a test for E6/E7 transcripts of human papillomavirus type 16 serve as a diagnostic tool for the detection of micrometastasis in cervical cancer? | Q71920501 |
| | Positive cervical smear with subsequent normal colposcopy and histology--frequency of CIN in a long-term follow-up | Q72430739 |
| | When the cervical Pap smear is positive | Q72854125 |
| | The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR | Q73108013 |
| | Detection of human papillomavirus mRNA and cervical cancer cells in peripheral blood of cervical cancer patients with metastasis | Q73132163 |
| | DNA binding and bending by the human papillomavirus type 16 E2 protein. Recognition of an extended binding site | Q73174536 |
| | Molecular biomarker-based screening for early detection of cervical cancer | Q73524905 |
| | The cervical cancer screening programme in Norway, 1992-2000: changes in Pap smear coverage and incidence of cervical cancer | Q74500028 |
| | Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types | Q78519639 |
| | CIN 2/3 and cervical cancer after an ASCUS pap smear. A 7-year, prospective study of the Norwegian population-based, coordinated screening program | Q79365148 |
| | The clinical significance of class III cervical Pap smear | Q79420863 |
| | Pap smear screening in women under 30 in the Norwegian Coordinated Cervical Cancer Screening Program, with a comparison of immediate biopsy vs Pap smear triage of moderate dysplasia | Q79739634 |
| | Expression of E6/E7 mRNA from 'high risk' human papillomavirus in relation to CIN grade, viral load and p16INK4a | Q79978136 |
| | CIN 2/3 and cervical cancer in an organised screening programme after an unsatisfactory or a normal Pap smear: a seven-year prospective study of the Norwegian population-based screening programme | Q80110534 |
| | The risk of false-positive histology according to the reason for colposcopy referral in cervical cancer screening: a blind revision of all histologic lesions found in the NTCC trial | Q80223714 |
| | Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications | Q80509739 |
| | The human papillomavirus type 18 E6 oncoprotein induces Vascular Endothelial Growth Factor 121 (VEGF121) transcription from the promoter through a p53-independent mechanism | Q80747944 |
| | Comparison of human papillomavirus testing and cervical cytology with colposcopic examination and biopsy in cervical cancer screening in a cohort of patients with Sjogren's syndrome | Q80828442 |
| | Human papillomavirus E6/E7 mRNA expression in women younger than 30 years of age | Q81193479 |
| | Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear | Q81258510 |
| | A study of the impact of adding HPV types to cervical cancer screening and triage tests | Q81290015 |
| | Assessment of human papillomavirus mRNA detection over time in cervical specimens collected in liquid based cytology medium | Q81304669 |
| | Screening histories of women with CIN 2/3 compared with women diagnosed with invasive cervical cancer: a retrospective analysis of the Norwegian Coordinated Cervical Cancer Screening Program | Q81845415 |
| | Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening | Q83603494 |
| | Efficiency of the APTIMA HPV Assay for detection of HPV RNA and DNA targets | Q84341096 |
| | Comparison of cytology, colposcopy, HPV typing and biomarker analysis in cervical neoplasia | Q84365208 |
| | Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3 | Q84748387 |
| | Role of high-risk human papillomavirus (HPV) mRNA testing in the prediction of residual disease after conisation for high-grade cervical intraepithelial neoplasia | Q84758055 |
| | Human papillomavirus testing as a screening tool for cervical cancer | Q93934270 |
| | Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer | Q95720944 |
| | Structure and transcription of human papillomavirus sequences in cervical carcinoma cells | Q41914039 |
| | Assessment of HPV-mRNA test to predict recurrent disease in patients previously treated for CIN 2/3. | Q42233345 |
| | Human papillomavirus type 16 E6 and E7 cooperate to increase epidermal growth factor receptor (EGFR) mRNA levels, overcoming mechanisms by which excessive EGFR signaling shortens the life span of normal human keratinocytes | Q42503546 |
| | Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer | Q42604851 |
| | Splice sites of human papillomavirus type 16 E6 gene or heterologous gene required for transformation by E7 and accumulation of E7 RNA. | Q42630432 |
| | Uniformity of the splicing pattern of the E6/E7 transcripts in human papillomavirus type 16-transformed human fibroblasts, human cervical premalignant lesions and carcinomas | Q42631746 |
| | The E6 variant proteins E6I-E6IV of human papillomavirus 16: expression in cell free systems and bacteria and study of their interaction with p53. | Q42638228 |
| | The majority of viral-cellular fusion transcripts in cervical carcinomas cotranscribe cellular sequences of known or predicted genes | Q42650642 |
| | Performance of ProEx C and PreTect HPV-Proofer E6/E7 mRNA tests in comparison with the hybrid capture 2 HPV DNA test for triaging ASCUS and LSIL cytology | Q43524242 |
| | DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia | Q43572262 |
| | Association of human papillomavirus types 16 and 18 E6 proteins with p53. | Q43701619 |
| | Isolation of RNA from residual BD SurePath liquid-based cytology specimens and detection of HPV E6/E7 mRNA using the PreTectt HPV-Proofer assay | Q43773337 |
| | Summary and recommendations of the workshop on uterine-cervical cancer | Q44034833 |
| | Identification of the protein encoded by the E6 transforming gene of bovine papillomavirus | Q44382490 |
| | Cervical cytology: The need for routine screeningin the sexually active adolescent | Q44439087 |
| | Human papillomavirus DNA and E6/E7 mRNA testing as triage in liquid-based cytology samples from primary screening | Q44458307 |
| | The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. | Q44527945 |
| | Human papillomavirus types 6 and 16 in cooperation with Ha-ras transform secondary rat embryo fibroblasts | Q44587526 |
| | Diagnostic and prognostic validity of the human papillomavirus E6/E7 mRNA test in cervical cytological samples of HC2-positive patients. | Q45002487 |
| | Disruption of the E2 gene is a common and early event in the natural history of cervical human papillomavirus infection: a longitudinal cohort study | Q45243670 |
| | Analytical performance of RNA isolated from BD SurePath™ cervical cytology specimens by the PreTect™ HPV-Proofer assay | Q45254763 |
| | Optimal sampling devices for liquid-based procedure in screening for cervical cancer: comparison between cotton stick/Cytobrush and Cervex-Brush | Q45830213 |
| | Detection of human papillomavirus 16 transcriptional activity in cervical intraepithelial neoplasia grade III lesions and cervical carcinomas by nested reverse transcription-polymerase chain reaction and in situ hybridization. | Q45885475 |
| | Towards improved biomarker studies of cervical neoplasia: effects of precolposcopic procedures on gene expression patterns | Q46500031 |
| | Human papillomavirus 16 E6/E7 transcript and E2 gene status in patients with cervical neoplasia | Q47257373 |
| | Papillomavirus and p53. | Q48024480 |
| | Regulation of the Wnt/β-Catenin Signaling Pathway by Human Papillomavirus E6 and E7 Oncoproteins | Q26795741 |
| | Human Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia | Q26801768 |
| | E6/E7 mRNA testing for human papilloma virus-induced high-grade cervical intraepithelial disease (CIN2/CIN3): a promising perspective | Q28087374 |
| | The papillomavirus life cycle | Q28238578 |
| | Consequences in women of participating in a study of the natural history of cervical intraepithelial neoplasia 3 | Q28290764 |
| | Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia | Q28296557 |
| | Papillomaviruses and cancer: from basic studies to clinical application | Q29614745 |
| | Human papillomavirus is a necessary cause of invasive cervical cancer worldwide | Q29617514 |
| | Detection of human papillomavirus 16, 18, and 45 in women with ASC-US cytology and the risk of cervical precancer: results from the CLEAR HPV study | Q30300943 |
| | Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. | Q30423690 |
| | Comparison of human papillomavirus testing strategies for triage of women referred with low-grade cytological abnormalities | Q30456505 |
| | Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices | Q30487807 |
| | Quantitation and mapping of integrated human papillomavirus on human metaphase chromosomes using a fluorescence microscope imaging system | Q31161090 |
| | Evidence for a causal association between human papillomavirus and a subset of head and neck cancers | Q33180284 |
| | In situ epidermoid carcinoma of the cervix and vagina following radiotherapy for cervical cancer | Q33190194 |
| | Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies | Q33687873 |
| | Triage of women with minor cervical lesions: data suggesting a "test and treat" approach for HPV E6/E7 mRNA testing | Q33698073 |
| | A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo | Q33747434 |
| | HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review | Q33762996 |
| | Comparative evaluation of seven cell collection devices for cervical smears | Q33782939 |
| | Repression of the integrated papillomavirus E6/E7 promoter is required for growth suppression of cervical cancer cells. | Q33799928 |
| | Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression | Q33873015 |
| | Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. | Q33923869 |
| | Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible | Q33951232 |
| | Human papillomavirus immortalization and transformation functions | Q33962694 |
| | Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3 | Q33984185 |
| | Triage of women with low-grade cervical lesions--HPV mRNA testing versus repeat cytology | Q34019808 |
| | The human papillomavirus E6 oncogene represses a cell adhesion pathway and disrupts focal adhesion through degradation of TAp63β upon transformation | Q34042655 |
| | Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer | Q34046296 |
| | HPV E6/E7 mRNA testing is more specific than cytology in post-colposcopy follow-up of women with negative cervical biopsy | Q34048160 |
| | The 2001 Bethesda System: terminology for reporting results of cervical cytology | Q34124761 |
| | Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears | Q37310663 |
| | Human papillomavirus and molecular considerations for cancer risk | Q37315925 |
| | Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting | Q37355500 |
| | The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle | Q37395003 |
| | Centrosome overduplication, chromosomal instability, and human papillomavirus oncoproteins | Q37424993 |
| | Accuracy of cervical specimens obtained for biomarker studies in women with CIN3. | Q37440922 |
| | The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis | Q37449263 |
| | Comparative effectiveness study on human papillomavirus detection methods used in the cervical cancer screening programme | Q37516596 |
| | Human Papillomaviruses and Their Possible Role in Squamous Cell Carcinomas | Q37711514 |
| | Self-collected HPV testing improves participation in cervical cancer screening: a systematic review and meta-analysis. | Q38101700 |
| | Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types | Q38123772 |
| | Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis | Q38179114 |
| | E6/E7 mRNA expression analysis: a test for the objective assessment of cervical adenocarcinoma in clinical prognostic procedure. | Q38344431 |
| | Gene expression-based prognostic and predictive tools in breast cancer | Q38421414 |
| | Model systems of human papillomavirus-associated disease | Q38604326 |
| | The human papillomavirus 16 European-T350G E6 variant can immortalize but not transform keratinocytes in the absence of E7. | Q38839864 |
| | Randomized Intervention of Self-Collected Sampling for Human Papillomavirus Testing in Under-Screened Rural Women: Uptake of Screening and Acceptability | Q38939561 |
| | Human papillomavirus (HPV) type 16 and 33 E6/E7 region transcripts in tonsillar carcinomas can originate from integrated and episomal HPV DNA | Q39100082 |
| | The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes | Q39101956 |
| | Comparison of the sensitivities of three commercial assays for detection of the high risk HPV types 16, 18 and 45. | Q39145081 |
| | Disruption of repressive p130-DREAM complexes by human papillomavirus 16 E6/E7 oncoproteins is required for cell-cycle progression in cervical cancer cells | Q39495625 |
| | Current concepts of intraepithelial neoplasia in the uterine cervix (CIN). | Q39511132 |
| | Centrosome abnormalities and genomic instability by episomal expression of human papillomavirus type 16 in raft cultures of human keratinocytes | Q39606567 |
| | PCR in situ hybridisation detection of HPV 16 in fixed CaSki and fixed SiHa cell lines | Q39637401 |
| | Dysplasia. A real concept or a misnomer? | Q39717216 |
| | Comparison of cervical Pap smears with subsequent diagnosis of cervical carcinoma an analysis of Arkansas health department Pap smears for 1970 and 1971 | Q39750705 |
| | Apicidin down-regulates human papillomavirus type 16 E6 and E7 transcripts and proteins in SiHa cervical cancer cells. | Q39952922 |
| | Significance of dysplasia | Q39998056 |
| | The E6-E7 region of human papillomavirus type 18 is sufficient for transformation of NIH 3T3 and rat-1 cells | Q40141212 |
| | E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells | Q40599227 |
| | Down-regulation of human papillomavirus E6/E7 oncogene by arsenic trioxide in cervical carcinoma cells | Q40690286 |
| | Human papillomavirus mRNA and DNA testing in women with atypical squamous cells of undetermined significance: A prospective cohort study. | Q40744991 |
| | Role of papillomavirus oncogenes in human cervical cancer: transgenic animal studies | Q40752594 |
| | Use of Cytology, E6/E7 mRNA, and p16INK4a-Ki-67 to Define the Management of Human Papillomavirus (HPV)-Positive Women in Cervical Cancer Screening | Q40853468 |
| | The human papillomavirus E7 protein as a transforming and transactivating factor | Q40854559 |
| | Cellular and molecular alterations in human epithelial cells transformed by recombinant human papillomavirus DNA. | Q40856848 |
| | Human papillomavirus 18 oncoproteins E6 and E7 enhance irradiation- and chemotherapeutic agent-induced apoptosis in p53 and Rb mutated cervical cancer cell lines | Q40941329 |
| | Meta-analysis of Pap test accuracy | Q40989993 |
| | Human papillomavirus type 33 DNA and E6-E7 transcripts in late passages of the UT-DEC-1 vaginal keratinocyte cell line | Q41032822 |
| | Barriers and Facilitators to Cervical Cancer Screening Among Women in Rural Ontario, Canada: The Role of Self-Collected HPV Testing | Q41057743 |
| | Biologic activity of human papillomavirus type 16 E6/E7 cDNA clones isolated from SiHa cervical carcinoma cell line | Q41406316 |
| | Possible role for human papillomavirus 16 in squamous cell carcinoma of the finger | Q41418698 |
| | The E6 gene of human papillomavirus type 16 is sufficient for transformation of baby rat kidney cells in cotransfection with activated Ha-ras | Q41463470 |
| | Transformation by human papillomavirus type 16 (HPV16) DNA but not HPV6b DNA is enhanced by addition of the human cytomegalovirus enhancer | Q41612270 |
| | Predictive power of circulating miRNAs in detecting colorectal cancer | Q41666017 |
| | NucliSENS EasyQ HPV v1 test - Testing for oncogenic activity of human papillomaviruses. | Q50734604 |
| | HPV mRNA test in women with minor cervical lesions: experience of the University Hospital of North Norway. | Q51760001 |
| | Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. | Q52584352 |
| | Loss of gene function as a consequence of human papillomavirus DNA integration. | Q53275559 |
| | Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. | Q53360347 |
| | Alterations in physical state and expression of human papillomavirus type 18 DNA following crisis and establishment of immortalized ectocervical cells. | Q53463058 |
| | Identification of cellular targets for the human papillomavirus E6 and E7 oncogenes by RNA interference and transcriptome analyses. | Q53544703 |
| | Bmi-1 cooperates with human papillomavirus type 16 E6 to immortalize normal human oral keratinocytes. | Q53582850 |
| | A statistical model of the natural history of cervical carcinoma based on a prospective study of 557 cases | Q53609652 |
| | High-throughput cervical cancer screening using intracellular human papillomavirus E6 and E7 mRNA quantification by flow cytometry. | Q53668937 |
| | Human papillomavirus and cervical cancer | Q54023273 |
| | Comparison of oncogenic HPV type-specific viral DNA load and E6/E7 mRNA detection in cervical samples: results from a multicenter study. | Q54277497 |
| | High risk human papillomavirus genotyping in clinical samples: evaluation of different commercial tests. | Q54377755 |
| | Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program. | Q54476876 |
| | Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens. | Q54510032 |
| | The natural history of human papillomavirus infection and cervical intraepithelial neoplasia among young women in the Guanacaste cohort shortly after initiation of sexual life. | Q54561362 |
| | PCR testing of pooled longitudinally collected cervical specimens of women to increase the efficiency of studying human papillomavirus infection. | Q54683835 |
| | Human papillomavirus and risk factors for cervical cancer in Chennai, India: a case-control study. | Q54759768 |
| | Prevalence of human papillomavirus in women with invasive cervical carcinoma by HIV status in Kenya and South Africa | Q58280163 |
| | Proliferative defects in dyskeratosis congenita skin keratinocytes are corrected by expression of the telomerase reverse transcriptase, TERT, or by activation of endogenous telomerase through expression of papillomavirus E6/E7 or the telomerase RNA c | Q61051287 |
| | HPV mRNA Testing in Triage of Women with ASC-US Cytology May Reduce the Time for CIN2+ Diagnosis Compared with Repeat Cytology | Q61687963 |
| | Correlation of colposcopy and histology in cervical biopsies positive for CIN and/or HPV infection | Q67868396 |
| | Papillomaviruses in human cancer | Q70169481 |
| | Conservation of E6 and E7 regions of human papillomavirus types 16 and 18 present in cervical cancers | Q70173557 |
| | Cervical cancer--intraepithelial neoplasia, severe dysplasia, invasive cancer of cervix, DES exposure | Q70632315 |
| | Screening strategies for cervical cancer and cervical intraepithelial neoplasia | Q70789532 |
| | Screening protocols for cervical neoplastic disease | Q71003889 |
| | Are human papillomavirus infections not necessary or sufficient causal factors for invasive cancer of the cervix? | Q71819969 |
| | MassARRAY spectrometry is more sensitive than PreTect HPV-Proofer and consensus PCR for type-specific detection of high-risk oncogenic human papillomavirus genotypes in cervical cancer | Q34205793 |
| | Meta-analysis on prevalence and attribution of human papillomavirus types 52 and 58 in cervical neoplasia worldwide | Q34207423 |
| | Immortalization of distinct human mammary epithelial cell types by human papilloma virus 16 E6 or E7. | Q34368179 |
| | Feasibility Study of a Human Papillomavirus E6 Oncoprotein Test for Diagnosis of Cervical Precancer and Cancer | Q34433015 |
| | The promise of global cervical-cancer prevention | Q34468217 |
| | HPV mRNA is more specific than HPV DNA in triage of women with minor cervical lesions | Q34535660 |
| | Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas | Q34569181 |
| | Human papillomavirus and cervical cancer | Q34580052 |
| | Evaluation of cervical cytology | Q34582965 |
| | Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer | Q34596772 |
| | Prognostic value of HPV E6/E7 mRNA assay in women with negative colposcopy or CIN1 histology result: a follow-up study | Q34608714 |
| | PreTect HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses | Q34611368 |
| | Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis | Q34641385 |
| | Virus transcript levels and cell growth rates after naturally occurring HPV16 integration events in basal cervical keratinocytes. | Q34852955 |
| | Post-translational control of IL-1β via the human papillomavirus type 16 E6 oncoprotein: a novel mechanism of innate immune escape mediated by the E3-ubiquitin ligase E6-AP and p53. | Q34916951 |
| | RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells | Q34977316 |
| | Alteration of cell cycle in cervical tumor associated with human papillomavirus: cyclin-dependent kinase inhibitors | Q35032710 |
| | Evaluation of a new DNA test for detection of carcinogenic human papillomavirus | Q35139772 |
| | Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test | Q35140046 |
| | Transcriptome signature of irreversible senescence in human papillomavirus-positive cervical cancer cells | Q35163096 |
| | Detection of precancerous cervical lesions is differential by human papillomavirus type | Q35163630 |
| | Centrosomes, genomic instability, and cervical carcinogenesis | Q35168219 |
| | Type-specific human papillomavirus E6/E7 mRNA detection by real-time PCR improves identification of cervical neoplasia | Q35530550 |
| | Centrosome abnormalities and genomic instability induced by human papillomavirus oncoproteins | Q35573713 |
| | Effect of an antepartum Pap smear on the coverage of a cervical cancer screening programme: a population-based prospective study | Q35622877 |
| | Towards a "Sample-In, Answer-Out" Point-of-Care Platform for Nucleic Acid Extraction and Amplification: Using an HPV E6/E7 mRNA Model System | Q35660073 |
| | Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China | Q35816897 |
| | Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells | Q35838905 |
| | Translation of the human papillomavirus type 16 E7 oncoprotein from bicistronic mRNA is independent of splicing events within the E6 open reading frame | Q35850926 |
| | Combined external quality assessment of cytology and histology opinions: a pilot scheme for a cluster of five laboratories | Q37184793 |
| | Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison | Q37239453 |
| | Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study | Q37281729 |
| | Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia | Q37302072 |
| | Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein | Q35880696 |
| | The Human Papillomavirus E6 PDZ Binding Motif: From Life Cycle to Malignancy | Q35895297 |
| | Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds | Q36023019 |
| | The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test | Q36029632 |
| | 5-type HPV mRNA versus 14-type HPV DNA test: test performance, over-diagnosis and overtreatment in triage of women with minor cervical lesions | Q36046119 |
| | Beyond human papillomavirus: the cervix, exogenous secondary factors, and the development of cervical precancer and cancer | Q36116841 |
| | High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology | Q36118590 |
| | Human papillomavirus type 58: the unique role in cervical cancers in East Asia | Q36150544 |
| | Laboratory and clinical aspects of human papillomavirus testing | Q36311573 |
| | Prevalence and determinants of human papillomavirus infection and cervical lesions in HIV-positive women in Kenya | Q36385334 |
| | A comparison of human papillomavirus genotype-specific DNA and E6/E7 mRNA detection to identify anal precancer among HIV-infected men who have sex with men. | Q36514226 |
| | Intermethod variation in detection of human papillomavirus DNA in cervical smears | Q36525380 |
| | Use of multiple PCR primer sets for optimal detection of human papillomavirus | Q36537504 |
| | Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions | Q36633110 |
| | Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies | Q36644814 |
| | Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis | Q36647828 |
| | Comparing the performance of six human papillomavirus tests in a screening population | Q36663594 |
| | Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis | Q36670753 |
| | Triage of HPV positive women in cervical cancer screening | Q36679896 |
| | Relation of p53 tumor suppressor protein expression to human papillomavirus (HPV) DNA and to cellular atypia in male genital warts and in premalignant lesions | Q36691643 |
| | Human papillomavirus oncogenic expression in the dysplastic portio; an investigation of biopsies from 190 cervical cones | Q36694878 |
| | Human papillomavirus type 16 transformation of primary human embryonic fibroblasts requires expression of open reading frames E6 and E7 | Q36781114 |
| | Identification of human papillomavirus type 18 transforming genes in immortalized and primary cells | Q36781685 |
| | Suppression in vivo of human papillomavirus type 18 E6-E7 gene expression in nontumorigenic HeLa X fibroblast hybrid cells. | Q36783824 |
| | Analysis of integrated human papillomavirus type 16 DNA in cervical cancers: amplification of viral sequences together with cellular flanking sequences. | Q36801152 |
| | Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing | Q36815006 |
| | The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes | Q36831207 |
| | The link between integration and expression of human papillomavirus type 16 genomes and cellular changes in the evolution of cervical intraepithelial neoplastic lesions | Q36861078 |
| | Integration of human papillomavirus type 16 DNA sequences: a possible early event in the progression of genital tumors. | Q36919390 |
| | Biochemical and functional interactions of human papillomavirus proteins with polycomb group proteins | Q37015721 |
| | Pitfalls in the epidemiologic classification of human papillomavirus types associated with cervical cancer using polymerase chain reaction: driver and passenger | Q37076397 |
| | Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study | Q37137085 |
| | Human papillomavirus DNA and e6/e7 mRNA status in relation to survival of patients treated for cervical squamous cell carcinoma | Q37183629 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P304 | page(s) | 866 | |
| P577 | publication date | 2018-12-21 | |
| P1433 | published in | Journal of public health in Africa | Q27724363 |
| P1476 | title | The potential of RNA as a target for national screening of pre-cancer | |
| P478 | volume | 9 | |